MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
6.18EPS Dil.
0.47P/E
19.52MMarket Cap
Quarterly Revenue
FRC
•
in mil. unless spec.
Year
Q1
Q2
Q3
Q4
FY
2022
13
18
10
11
41
2023
9
- -
6
1
49
2024
65
- -
- -
- -
- -
Working Capital
FRC
•
in mil. unless spec.
Mar'23
Jun'23
Sep'24
Total Current Assets
120
108
88
Cash, Cash Equivalents & STI
112
101
82
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
24
20
9
Payables & Accruals
21
11
6
ST Debt
1
1
1
Deferred Revenue
2
0
- -
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
TTM
FRC
11.82
3.74
1.38
- -
- -
- -
- -
- -
- -
12.63
0.78
1.38
6.35
4.54
6.54
7.33
15.82
Revenue per ShareRevenue per Share
-217.72
-183.28
-129.44
-105.95
-67.17
-22.02
-27.07
-23.19
-12.13
1.45
-19.34
-4.73
-10.10
-8.99
-8.75
-4.78
6.18
Basic EPS, GAAPBasic EPS, GAAP
-201.72
-173.02
-164.52
-102.33
-63.22
-19.85
-19.44
-19.92
-10.38
1.87
-10.28
-8.33
7.33
-5.81
-7.91
-7.88
-8.43
Free Cash Flow per Basic ShareFree Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per ShareDividend per Share
-907.56
-1,031.33
-1,160.77
-1,048.49
-497.73
-112.50
-114.30
-91.42
-103.63
-94.80
-60.91
-62.88
-49.72
-58.22
-56.20
-60.93
-52.47
Book Value per ShareBook Value per Share
290.09
249.39
121.00
24.24
26.89
40.19
41.44
34.77
24.17
27.46
14.25
12.96
14.03
7.35
7.87
3.70
12.21
Tangible Book Value per ShareTangible Book Value per Share